Topic: safety accuracy concerns

OpenAI and FDA in Talks to Use AI for Drug Evaluations

The FDA is in talks with OpenAI and others to develop AI tools like cderGPT to speed up drug evaluations, potentially reducing approval timelines by years. AI could address bottlenecks in late-stage drug reviews, but challenges remain in ensuring accuracy and minimizing risks from algorithmic...